Skip to main content
. 2020 Sep 11;6(2):529–542. doi: 10.1016/j.bioactmat.2020.08.017

Fig. 4.

Fig. 4

Neural mitochondria-targeting and transport across the BBB of the biomimetic nanosystems in vitro and in vivo. (A) Neuronal cellular uptake via FCM analysis of differentiated HT22 cells after incubation with different Cou6-tagged formulations. (B) FCM analysis of differentiated HT22 cells treated with various Cou6-tagged formulations after crossing the bEnd.3-HT22 cells co-culture BBB model in vitro. (C) Comparison of the selective targeting ability of the DDS (RVG/TPP-MASLNs-Cou6) between HT22 neurons and astrocytes. (D) Comparison of the remaining ability of the DDS (RVG/TPP-MASLNs-Cou6) for selective targeting after crossing the bEnd.3-HT22 cells or bEnd.3-astrocytes co-culture BBB model in vitro by FCM. * indicates p < 0.05. (E) Colocalization of various Cou6-tagged formulations into mitochondria in differentiated HT22 cells. Cou6 (green) and MitoTracker for mitochondria staining (red) were recorded. Scale bars represent 20 μm. R represents the co-localization coefficient determined using Image J software. (F) In vivo brain-targeting ability. Biodistribution of DIR contained in various formulations determined by IVIS Lumina II. (G) Relative fluorescence signal of brain homogenate after in vivo image acquisition. Data are presented as means ± SD (n = 3). *p < 0.05 compared with MASLNs.